Streetbeat News

ARDS

Aridis Pharmaceuticals Inc

Employees

Industry

Research and Development in Biotechnology

aridis is a privately held infectious diseases focused company in san jose, ca, usa. aridis’ advanced formulation and delivery technologies are combined with proprietary products portfolio to create potent drug candidates that are packaged into convenient to administer, "ready-to-use" formats.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

HC Wainwright & Co. analyst Vernon Bernardino has reiterated a 'Buy' rating on Aridis Pharmaceuticals (OTC:ARDS) and maintained a $2 price target.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 12:05 pm

Aridis Pharmaceuticals reported Q3 earnings per share (EPS) of $0.00, up from $(0.47) year over year (YoY). The company's sales also increased to $417.00K from $399.00K YoY.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 8:17 pm

HC Wainwright & Co. analyst Vernon Bernardino maintains a 'Buy' rating on Aridis Pharmaceuticals (OTC:ARDS) but has lowered the price target from $10 to $2.

Portfolio Pulse from Benzinga Newsdesk

October 20, 2023 | 5:54 pm

In Tuesday's after-market session, several healthcare stocks saw significant movement. Gainers included Etao International Co (ETAO), Virax Biolabs Group (VRAX), Aprea Therapeutics (APRE), Reneo Pharmaceuticals (RPHM), Ra Medical Systems (RMED), and Mesoblast (MESO). Losers included Amarin Corp (AMRN), EUDA Health Holdings (EUDA), ViewRay (VRAY), Aridis Pharmaceuticals (ARDS), Oncology Institute (TOI), and Theriva Biologics (TOVX).

Portfolio Pulse from Benzinga Insights

July 18, 2023 | 9:32 pm

The article lists the stocks that gained and lost the most in Tuesday's mid-day session. Some of the gainers include Pieris Pharmaceuticals, The Singing Machine Company, Biophytis, iCAD, Aridis Pharmaceuticals, and The Charles Schwab Corporation. The losers include 9 Meters Biopharma, Fangdd Network Group, Lixte Biotechnology Holdings, Masimo Corporation, and Aptevo Therapeutics.

Portfolio Pulse from Lisa Levin

July 18, 2023 | 5:00 pm

Aridis Pharmaceuticals Inc (NASDAQ:ARDS) shares are gaining after the company announced positive feedback from the European Medicines Agency on its proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301. The agreements by the EMA were similar to those agreed by the FDA. The company's shares are up 29.40% at $0.34 during the premarket session.

Portfolio Pulse from Vandana Singh

July 18, 2023 | 1:09 pm

During Tuesday's pre-market session, several healthcare stocks experienced significant movements. Biophytis, Aridis Pharmaceuticals, Hyperfine, Karyopharm Therapeutics, Genprex, and Lantern Pharma saw increases in their share prices, while 9 Meters Biopharma, Lixte Biotech Hldgs, Masimo, CEL-SCI, EUDA Health Holdings, and First Wave BioPharma experienced declines.

Portfolio Pulse from Benzinga Insights

July 18, 2023 | 1:06 pm

Biophytis S.A. (BPTS) shares surged 53.9% after signing a partnership with SEQENS to produce Sarconeos (BIO101) active compound. Aridis Pharmaceuticals, Inc. (ARDS) shares gained 41.8% after EMA announced positive feedback on the company's proposed Phase 3 study AR-301. Karyopharm Therapeutics Inc. (KPTI) rose 26.1% after receiving FDA Fast Track Designation for Selinexor for Myelofibrosis. 9 Meters Biopharma, Inc. (NMTR) fell 59% and Masimo Corporation (MASI) fell 27.3% after reporting weak preliminary revenue results for Q2.

Portfolio Pulse from Lisa Levin

July 18, 2023 | 12:12 pm

Aridis Pharmaceuticals' shares are trading higher following positive feedback from the European Medicines Agency (EMA) on the company's proposed Phase 3 study AR-301 for pneumonia caused by Staphylococcus aureus in mechanically ventilated hospitalized patients.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2023 | 10:12 am

In Monday's after-market session, several health care stocks saw significant movement. Aridis Pharmaceuticals (ARDS), Dare Bioscience (DARE), Karyopharm Therapeutics (KPTI), Cue Health (HLTH), Cardio Diagnostics Hldgs (CDIO), and Petros Pharma (PTPI) all saw gains, with ARDS leading with an 89.5% increase. On the other hand, 9 Meters Biopharma (NMTR), Masimo (MASI), CEL-SCI (CVM), EUDA Health Holdings (EUDA), First Wave BioPharma (FWBI), and Acumen Pharmaceuticals (ABOS) all experienced losses, with NMTR falling by 60%.

Portfolio Pulse from Benzinga Insights

July 17, 2023 | 9:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.